An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

@article{Byers2013AnET,
  title={An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.},
  author={Lauren A. Byers and Lixia Diao and Jing Wang and Pierre Saintigny and Luc Girard and Michael Peyton and Li Shen and Youhong Fan and Uma Giri and Praveen K Tumula and Monique B Nilsson and Jayanthi P. Gudikote and Hai L Tran and Robert J. G. Cardnell and David J. Bearss and Steven L. Warner and Jason M. Foulks and Steven B. Kanner and Varsha Gandhi and Nancy L. Krett and Steven T. Rosen and Edward S. Kim and Roy S. Herbst and George R. Blumenschein and James S. J. Lee and Scott Michael Lippman and K. Kian Ang and Gordon B. Mills and Waun Ki Hong and John N. Weinstein and Ignacio Wistuba and Kevin R. Coombes and John D. Minna and John V. Heymach},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 1},
  pages={279-90}
}
PURPOSE Epithelial-mesenchymal transition (EMT) has been associated with metastatic spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated a robust 76-gene EMT signature using gene expression profiles from four platforms using non-small cell lung carcinoma (NSCLC) cell lines and patients treated in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study. EXPERIMENTAL DESIGN We conducted an integrated gene expression… CONTINUE READING
Highly Influential
This paper has highly influenced 29 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS